A citation-based method for searching scientific literature

Carmen Behrens, Pedro Rocha, Edwin R Parra, Lei Feng, Jaime Rodriguez-Canales, Luisa M Solis, Barbara Mino, Jianjun Zhang, Don L Gibbons, Boris Sepesi, David Rice, John V Heymach, Cesar Moran, Chad J Creighton, J Jack Lee, Humam Kadara, Ignacio I Wistuba. Clin Lung Cancer 2021
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
Jorien Minnema-Luiting, Heleen Vroman, Joachim Aerts, Robin Cornelissen. Int J Mol Sci 2018
35
33

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Namrata S Patil, Luisella Righi, Hartmut Koeppen, Wei Zou, Stefania Izzo, Federica Grosso, Roberta Libener, Marco Loiacono, Valentina Monica, Consuelo Buttigliero,[...]. J Thorac Oncol 2018
32
33

Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona, Eleftherios P Diamandis, Ivan M Blasutig. BMC Med 2016
515
33

Classifying Cancers Based on T-cell Infiltration and PD-L1.
Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, Mark J Smyth. Cancer Res 2015
783
33

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Rong Rong Huang, Jason Jalil, James S Economou, Bartosz Chmielowski, Richard C Koya, Stephen Mok, Hooman Sazegar, Elizabeth Seja, Arturo Villanueva, Jesus Gomez-Navarro,[...]. Clin Cancer Res 2011
104
33


Tumor microenvironment: Sanctuary of the devil.
Lanlan Hui, Ye Chen. Cancer Lett 2015
316
33

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, Diva R Salomao, Hideto Tamura, Fumiya Hirano, Dallas B Flies, Patrick C Roche, Jun Lu, Gefeng Zhu, Koji Tamada,[...]. Nat Med 2002
33

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
Loise M Francisco, Victor H Salinas, Keturah E Brown, Vijay K Vanguri, Gordon J Freeman, Vijay K Kuchroo, Arlene H Sharpe. J Exp Med 2009
33


Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies.
Edwin Roger Parra, Mei Jiang, Luisa Solis, Barbara Mino, Caddie Laberiano, Sharia Hernandez, Swati Gite, Anuj Verma, Michael Tetzlaff, Cara Haymaker,[...]. Cancers (Basel) 2020
17
33

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.
Marcella Tazzari, Silvia Brich, Alessandra Tuccitto, Fabio Bozzi, Valeria Beretta, Rosalin D Spagnuolo, Tiziana Negri, Silvia Stacchiotti, Marcello Deraco, Dario Baratti,[...]. J Immunol Res 2018
11
33

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter Mottram, Melina Evdemon-Hogan, Jose R Conejo-Garcia, Lin Zhang, Matthew Burow,[...]. Nat Med 2004
33

Gene-engineered T cells for cancer therapy.
Michael H Kershaw, Jennifer A Westwood, Phillip K Darcy. Nat Rev Cancer 2013
299
33

Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.
Peter DeLong, Richard G Carroll, Adam C Henry, Tomoyuki Tanaka, Sajjad Ahmad, Michael S Leibowitz, Daniel H Sterman, Carl H June, Steven M Albelda, Robert H Vonderheide. Cancer Biol Ther 2005
84
33

Tolerance and exhaustion: defining mechanisms of T cell dysfunction.
Andrea Schietinger, Philip D Greenberg. Trends Immunol 2014
333
33

Mesothelioma epidemiology, carcinogenesis, and pathogenesis.
Haining Yang, Joseph R Testa, Michele Carbone. Curr Treat Options Oncol 2008
158
33

Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
G Pasello, G Zago, F Lunardi, L Urso, I Kern, G Vlacic, F Grosso, M Mencoboni, G L Ceresoli, M Schiavon,[...]. Ann Oncol 2018
46
33

Multiplex Immunofluorescence Assays.
Alejandro Francisco-Cruz, Edwin Roger Parra, Michael T Tetzlaff, Ignacio I Wistuba. Methods Mol Biol 2020
16
33


Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.
Swati Khanna, Anish Thomas, Daniel Abate-Daga, Jingli Zhang, Betsy Morrow, Seth M Steinberg, Augusto Orlandi, Patrizia Ferroni, Jeffrey Schlom, Fiorella Guadagni,[...]. J Thorac Oncol 2016
70
33

Innate and adaptive immune cells in the tumor microenvironment.
Thomas F Gajewski, Hans Schreiber, Yang-Xin Fu. Nat Immunol 2013
33


Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
Edwin R Parra, Pamela Villalobos, Carmen Behrens, Mei Jiang, Apar Pataer, Stephen G Swisher, William N William, Jiexin Zhang, Jack Lee, Tina Cascone,[...]. J Immunother Cancer 2018
61
33

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
33

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Anna C Bibby, Selina Tsim, Nikolaos Kanellakis, Hannah Ball, Denis C Talbot, Kevin G Blyth, Nick A Maskell, Ioannis Psallidas. Eur Respir Rev 2016
109
33

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.
Edwin R Parra, Naohiro Uraoka, Mei Jiang, Pamela Cook, Don Gibbons, Marie-Andrée Forget, Chantale Bernatchez, Cara Haymaker, Ignacio I Wistuba, Jaime Rodriguez-Canales. Sci Rep 2017
116
33

Malignant mesothelioma: attributable risk of asbestos exposure.
R Spirtas, E F Heineman, L Bernstein, G W Beebe, R J Keehn, A Stark, B L Harlow, J Benichou. Occup Environ Med 1994
215
33

Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma.
A Lacourt, C Gramond, P Rolland, S Ducamp, S Audignon, P Astoul, S Chamming's, A Gilg Soit Ilg, M Rinaldo, C Raherison,[...]. Thorax 2014
74
33

A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.
Leeat Keren, Marc Bosse, Diana Marquez, Roshan Angoshtari, Samir Jain, Sushama Varma, Soo-Ryum Yang, Allison Kurian, David Van Valen, Robert West,[...]. Cell 2018
265
33

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
Edwin R Parra, Carmen Behrens, Jaime Rodriguez-Canales, Heather Lin, Barbara Mino, Jorge Blando, Jianjun Zhang, Don L Gibbons, John V Heymach, Boris Sepesi,[...]. Clin Cancer Res 2016
88
33


Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
S Cedrés, S Ponce-Aix, N Pardo-Aranda, A Navarro-Mendivil, A Martinez-Marti, J Zugazagoitia, I Sansano, M A Montoro, A Enguita, E Felip. Lung Cancer 2016
21
33

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
33

Radiation and immunotherapy: a synergistic combination.
Anusha Kalbasi, Carl H June, Naomi Haas, Neha Vapiwala. J Clin Invest 2013
167
33

Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma.
Lorena Losi, Federica Bertolini, Giorgia Guaitoli, Luca Fabbiani, Federico Banchelli, Andrea Ambrosini-Spaltro, Laura Botticelli, Letizia Scurani, Cinzia Baldessari, Fausto Barbieri,[...]. Int J Oncol 2019
11
33

Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Edwin R Parra, Pamela Villalobos, Barbara Mino, Jaime Rodriguez-Canales. Appl Immunohistochem Mol Morphol 2018
82
33

Reactive oxygen species a double-edged sword for mesothelioma.
Serena Benedetti, Barbara Nuvoli, Simona Catalani, Rossella Galati. Oncotarget 2015
45
33

Sexually dimorphic gene expression in mammalian somatic tissue.
Jörg Isensee, Patricia Ruiz Noppinger. Gend Med 2007
56
33

Sex disparities in cancer mortality and survival.
Michael B Cook, Katherine A McGlynn, Susan S Devesa, Neal D Freedman, William F Anderson. Cancer Epidemiol Biomarkers Prev 2011
229
33

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.
Christopher J D Wallis, Mohit Butaney, Raj Satkunasivam, Stephen J Freedland, Sandip P Patel, Omid Hamid, Sumanta K Pal, Zachary Klaassen. JAMA Oncol 2019
96
33

Reference values of lymphocyte subsets in the normal healthy adult Kuwaiti Arab population.
Salim A Kaaba, Suad Al Fadhli, Amal Khamis. Immunol Lett 2002
19
33

Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Aránzazu Lafuente-Sanchis, Ángel Zúñiga, Miriam Estors, Néstor J Martínez-Hernández, Antonio Cremades, María Cuenca, José M Galbis. Clin Lung Cancer 2017
18
33

Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.
Hui-Shan Huang, Harvey Yu-Li Su, Pei-Hsu Li, Po-Hui Chiang, Cheng-Hua Huang, Chien-Hsu Chen, Meng-Che Hsieh. Sci Rep 2018
13
33

Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.
Jonathan Ma, Sadhika Malladi, Andrew H Beck. Sci Rep 2016
13
33

Sex Differences in Using Systemic Inflammatory Markers to Prognosticate Patients with Head and Neck Squamous Cell Carcinoma.
Ching Ying Lin, Hyunwoo Kwon, Guillermo O Rangel Rivera, Xue Li, Dongjun Chung, Zihai Li. Cancer Epidemiol Biomarkers Prev 2018
6
33

PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Robert Brody, Yiduo Zhang, Marc Ballas, Mohd Kashif Siddiqui, Palvi Gupta, Craig Barker, Anita Midha, Jill Walker. Lung Cancer 2017
102
33


Sex disparities in head & neck cancer driver genes: An analysis of the TCGA dataset.
Neil Mundi, Farhad Ghasemi, Peter Y F Zeng, Stephenie D Prokopec, Krupal Patel, Hugh Andrew Jinwook Kim, Eric Di Gravio, Danielle MacNeil, Mohammed Imran Khan, Myung Woul Han,[...]. Oral Oncol 2020
8
33

Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer.
Mauricio S Caetano, Maya Hassane, Hieu T Van, Emmanuel Bugarin, Amber M Cumpian, Christina L McDowell, Carolina Gonzalez Cavazos, Huiyuan Zhang, Shanshan Deng, Lixia Diao,[...]. Nat Commun 2018
33
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.